Month: September 2026

– This integration of Firefly’s FDA 510(k)-cleared, AI-powered EEG/ERP technology follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, forming the country’s largest brain medicine clinical network –

KENMORE, N.Y. and NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF) today announced a strategic collaboration with Radial, operator of the country’s largest network of brain medicine clinics, to pursue the integration of Firefly’s FDA 510(k)-cleared, AI-powered Evoke™ EEG/ERP platform with RadialOS, Radial’s proprietary AI-native operating system for brain medicine.

The planned integration will incorporate objective measures of brain function into Radial’s diagnostic process, helping clinicians develop a more complete understanding of each patient, identify potentially appropriate treatment pathways, coordinate care and track outcomes over time. This integration aims to create a more informed and personalized approach to delivering brain-medicine treatments.

Radial develops the clinical infrastructure, reimbursement capabilities and AI-guided decision-support tools needed to expand access to advanced brain-medicine treatments. Its platform supports the delivery of therapies that include transcranial magnetic stimulation (“TMS”), medications and other interventional approaches, offered across its network of 27 clinics in seven states.

Firefly’s Evoke™ platform combines quantitative electroencephalography (“qEEG”) and event-related potential (“ERP”) testing with AI-powered analytics to provide clinicians with objective information about brain function. The platform is designed to help clinicians identify relevant brain-activity patterns, assess patients whose symptoms may overlap and monitor changes over time.

“Integrating Evoke™ with RadialOS represents a compelling opportunity to place objective, data-driven insights directly into the clinical workflow,” said Greg Lipschitz, Chief Executive Officer of Firefly. “Radial is building the infrastructure required to deliver advanced brain medicine at scale. We believe the combination of its operating platform and clinical reach with Firefly’s AI-powered brain-function technology could help clinicians make more informed decisions, personalize care and objectively measure how patients respond over time.”

The collaboration follows Radial’s August 2026 acquisition of the management services organization supporting Mindful Health Solutions, significantly expanding Radial’s clinical footprint and ability to deploy new brain-medicine technologies across a large patient population.

“Brain medicine treatments are advancing rapidly. It’s also true that most clinics are operating on outdated infrastructure,” said Owen Muir, M.D., co-founder and Chief Scientific Officer of Radial. “Clinicians need better tools to translate emerging evidence into personalized, real-world care. We believe integrating Firefly’s objective brain-function data into RadialOS can help close that gap—giving clinicians actionable information at the point of care and helping more patients reach the right treatment sooner.”

About Radial

Radial supports the country’s leading clinical network for brain medicine, expanding access to the world’s most advanced mental health treatments. Backed by General Catalyst, its clinical partners now include 27 clinics and more than 100 clinicians treating hundreds of thousands of patients each year, with a focus on high-acuity mental health conditions. This clinical network accepts most major insurance plans, including Medicare, Tricare, VA-CCN, Aetna, Cigna, United, and many Blues plans. By collaborating with its clinical partners to develop and implement clinical infrastructure, reimbursement tools, and RadialOS, its proprietary AI-guided decision support designed around novel psychiatry treatments like neuromodulation (e.g., TMS), medication (e.g., Spravato), and other interventional therapies, Radial is at the forefront of helping providers deliver the highest quality, most patient-centered and most innovative care, ensuring transformative brain medicine is accessible to all. Learn more at www.meetradial.com.

About Firefly Neuroscience

Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company advancing precision neuroscience, applying AI and large-scale electrophysiological data to give clinicians a more complete, objective picture of how an individual patient’s brain is functioning. Firefly’s proprietary database consists of over 200,000 EEG/ERP brain scans, which the Company believes to be the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared Evoke System is designed to support diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and PTSD.

Please visit www.fireflyneuro.com for more information.

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly, including statements regarding the anticipated benefits, scope, and results of the collaboration between Firefly and Radial, statements regarding Radial’s business, clinic network, and expansion plans, and statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Investor & Media Contacts

For Firefly
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com

For Radial
Kayli Watson
120/80 MKTG
radial@12080group.com

Vancouver, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce additional oxide-gold assays from the 2026 drill program at its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. These results have significantly expanded oxide gold mineralization both inside and outside of the 2026 Mineral Resource Estimate (“MRE”) pit-shell released on July 15, 2026 (see News Release). The focus of the 2026 20,000 meter drill program is resource expansion and conversion of the MRE.

NevGold CEO, Brandon Bonifacio, comments: “It is extremely encouraging to have thick intercepts of high-grade oxide gold grades over 1.00 g/t Au that have expanded mineralization inside and outside of the 2026 MRE pitshell. The initial 2026 drillholes at the Bullet Zone have delivered on expanding both oxide gold and antimony mineralization, and the grades intercepted have been higher than the average MRE grade profile. Our geological interpretation is that gold and antimony were deposited in the same general area during two separate mineralizing events, which explains why certain parts of the deposit are higher-grade oxide gold and others are higher-grade oxide antimony. This is important to highlight as it creates future operational and development flexibility as Limo is advanced. With two drill rigs and approximately 9,000 meters of drilling completed to date, and 33 drillholes with assays pending, our Technical Team continues to test the resource expansion potential with each drillhole. We are fully funded for the next 12-18 months with over $45 million in treasury, and our team is focused on delivering on one of the most important gold-antimony projects in the United States.” 

Key Highlights

• High-grade oxide gold mineralization significantly expanded outside 2026 MRE pit-shell with 1.06 g/t oxide Au over 42.7 meters:

• • LB26-007 Lower (expansion outside of 2026 pit-shell): 1.89 g/t oxide Au over 18.3 meters within 1.06 g/t oxide Au over 42.7 meters (terminated in 0.52 g/t oxide Au)
  • LB26-007 Upper (infill): 0.20% Sb over 16.8 meters

• High-grade oxide gold mineralization significantly expanded inside 2026 MRE pit-shell with 5.00 g/t oxide Au over 3.0 meters

• • LB26-004 (expansion inside of 2026 pit-shell): 5.00 g/t oxide Au over 3.0 meters within 1.23 g/t oxide Au over 27.4 meters
  • Drillhole LB26-004 converted unmineralized blocks within the 2026 MRE pit-shell, immediate mineralization expansion (Figure 1, Figure 2)

• Company remains fully funded for the next 12-18 months with +$45 million in treasury

• 40 holes completed, 33 holes with assays pending after this News Release

• Advancing Preliminary Economic Assessment (“PEA”) and Engineering Studies at Limo Butte 

Limo Butte Planned 2026-2027 Activities / Status Update
NevGold will continue its active exploration program at Limo Butte including:

• Continuing to drill test gold-antimony targets (~20,000 meters is planned in 2026 focused on the Bullet Zone / Armory Fault discoveries and resource conversion);

• Advancing metallurgical testwork (ongoing);

• Complete initial gold-antimony Mineral Resource Estimate (MRE) (completed, July 15);

• Advancing PEA / Engineering Studies (in process).

Figure 1 – Resurrection Ridge resource area with completed 2026 drilling. Figure includes outline of 2026 AuEq. resource pitshell, priority expansion area for ongoing 2026 drilling, and intercepts for completed 2026 drilling. Ongoing road and pad construction efforts are also shown, highlighting focused efforts to expand Au and Sb mineralization to the east under the dolomite thrust. To view image please click here

Figure 2 – Cross section with Au values from 2026 MRE block model and Au intercepts from all drilling along section. The drillholes in the 2026 drill program have expanded oxide mineralization both inside and outside of the recently announced 2026 MRE pit-shell. To view image please click here

2026 Drilling Results – Resurrection Ridge

Hole ID	Length, m*	g/t Au***	% Sb***	g/t AuEq**	From, m	To, m
LB26-004	27.4	1.23	–	1.23	164.6	192.0
Including	3.0	5.00	–	5.00	178.3	181.4
LB26-005	36.6	0.13	–	0.13	83.8	120.4
Including	10.7	0.20	0.09%	0.57	109.7	120.4
LB26-006	30.5	0.18	0.08%	0.47	68.6	99.1
Including	6.1	0.51	0.14%	1.06	74.7	80.8
LB26-007 Upper	16.8	–	0.20%	0.79	29.0	45.7
LB26-007 Lower	42.7	1.06	–	1.06	242.3	285.0
Including	18.3	1.89	–	1.89	263.7	281.9

*Downhole thickness reported; true width varies depending on drill hole dip and is approximately 70% to 90% of downhole thickness.
**The gold equivalents (“AuEq”) are based on assumed metals prices of US$3,000/oz of gold and US$40,000 per tonne of antimony, and assumed metals recoveries of 80% for gold and 75% for antimony.
***Values less than 0.05 g/t Au and 0.05% Sb not included.

Drillhole Orientation Details

Hole ID	Target Zone	Easting	Northing	Elevation (m)	Length (m)	Azimuth	Dip
LB26-004	RR	667217	4417168	2241	202.7	90	-80
LB26-005	RR	667217	4417167	2241	278.9	0	-90
LB26-006	RR	667217	4417168	2241	288.0	35	-70
LB26-007	RR	667173	4417250	2189	285.0	120	-60

Figure 3 – Limousine Butte Land Holdings and District Exploration Activity To view image please click here

ON BEHALF OF THE BOARD

“Signed”
Brandon Bonifacio, President & CEO

For further information, please contact Brandon Bonifacio at bbonifacio@nev-gold.com, call 604-337-4997, or visit our website at www.nev-gold.com.

Sampling Methodology, Quality Control and Quality Assurance
NevGold QA/QC protocols are followed on the Project and include insertion of duplicate, blank and standard samples in all drill holes. A 30g gold fire assay and multi-elemental analysis ICP-OES method was completed by ISO 17025 certified American Assay Labs, Reno.

Technical information contained in this news release has been reviewed and approved by Greg French, CPG, the Company’s Vice President, Exploration, who is NevGold’s Qualified Person (“QP”) under National Instrument 43-101 and responsible for technical matters of this release.

About the Company
NevGold is dedicated to discovering, de-risking, and rapidly advancing gold and critical metals projects across premier jurisdictions in Nevada and Idaho to drive shareholder value and strengthen US mineral security. The Company holds a 100% interest in the Limousine Butte (gold-antimony) and Cedar Wash (gold) projects in Nevada, and the Nutmeg Mountain (gold) and Zeus (copper) projects in Idaho. For more information, please visit www.nev-gold.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements

This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “suggest”, “indicate” and other similar words or statements that certain events or conditions “may” or “will” occur. Forward-looking statements include, but are not limited to, the proposed work programs at Limousine Butte, the exploration potential at Limousine Butte, the expansion of the  recently announced MRE at Limo Butte, and future potential project milestones such as the potential Preliminary Economic Assessment (“PEA”). Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements. Such risks include, but are not limited to, general economic, market and business conditions, and the ability to obtain all necessary regulatory approvals. There is some risk that the forward-looking statements will not prove to be accurate, that the management’s assumptions may not be correct or that actual results may differ materially from such forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein.

Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind’s clinical trial at Yale and Johns Hopkins

Vancouver, Canada, Sept. 17, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment  of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced that, following an invitation from the U.S. Food and Drug Administration (“FDA”), it testified at the FDA’s history-making psychedelic hearing in the nation’s capital on September 14, 2026. Clearmind’s Chief of Global Impact, Mary-Elizabeth Gifford, briefed a federal panel convened by the FDA to evaluate “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs.”

The history-making hearing marked a dedicated federal forum convened by the FDA to gather public input on the potential future therapeutic use of psychedelic drugs, bringing together senior FDA officials and federal partners from Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institutes of Health and the Veterans Health Administration.

Invited to address the question of “Patient Access” Gifford said: “At Clearmind Medicine, our clinical trial at Yale and Johns Hopkins have generated findings suggesting that a next-generation category of psychedelics, neuroplastogenic compounds, which retain the therapeutic benefits of neuroplasticity enhancement while eliminating the hallucinogenic effects of legacy psychedelics, may help mitigate the need for expensive supervised dosing. Our findings have led us to believe that this may represent a scalable treatment model that is a replicable and shareable opportunity for the future of American health.”

In addition to soliciting expertise on patient access, the FDA’s hearing also invited testimony on provider training and credentialing, patient safety, and best practices for data collection and standardization.

Tiffany R. Farchione, M.D., Director, Division of Psychiatry, Center for Drug Evaluation and Research (CDER) Office of New Drugs, sat on the day’s Federal Listening Panel, as did senior leadership from the Substance Abuse and Mental Health Services Administration (SAMHSA), the National Institute on Drug Abuse (NIDA), the Advanced Research Projects Agency for Health (ARPA-H) and the Veterans Health Administration. Approximately 1,800 participants attended the hearing in person and virtually.

At the hearing, Gifford told the FDA panel that next-generation psychedelic neuroplastogens that do not need expensive supervised dosing may reduce health disparities and achieve patient access for those with intractable substance use disorders and “myriad other diagnoses that could be treated safely under medical care.” 

She concluded: “This secures responsible patient access, not through new expensive frameworks that are yet to be built, but through America’s already existing primary care and VA resources.”

MEAI, Clearmind’s proprietary drug candidate for the treatment of AUD, a condition that affects one in ten Americans, and is considered a leading cause of preventable deaths for working age adults, is currently being evaluated in FDA-approved clinical trial at Yale University Medical School and Johns Hopkins University. MEAI is also among a limited number of non-hallucinogenic, psychedelic-derived neuroplastogen candidates to have advanced to a Phase 2a clinical trial.

“We are grateful to the FDA and federal health officials for leading this important national conversation and for its visionary encouragement of responsible biopharma innovation in addiction treatment, including the treatment of AUD,” said Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. Zuloff-Shani, Ph.D. added, “We appreciate the opportunity to contribute to this emerging technological field, with MEAI representing our commitment to developing innovative treatments that could ultimately be both effective and more accessible to patients. Mary-Elizabeth Gifford speaks for all of us at Clearmind, articulating our collective mission to bridge rigorous evidence-based research with federal policy that could potentially help us to accelerate improved care for patients across the US and globally.”

Gifford, Clearmind’s Chief of Global Impact, anchors the biopharma’s presence in New York City and Washington, D.C., and has been described by Spirituality & Health magazine as “the most quietly influential woman working in psychedelics today.” Her pro-bono contributions to the field of psychedelic medicine include chairing the steering committee for the Psychedelic Medicine Coalition Annual Federal Psychedelic Summit at the National Press Club and heading the non-profit Global Wellness Institute’s Psychedelics & Healing Initiative.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential therapeutic profile of neuroplastogenic compounds, the development and clinical advancement of MEAI, the potential benefits of the Company’s product candidates, the implications of its participation in the FDA hearing, and the Company’s plans, objectives and expectations regarding future research, development and commercialization activities. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

YardFlow brings Rail Vision’s perception technology to a broad range of rail operations and will support the Company’s expanding commercial collaboration with Railserve, a Marmon Rail company.

Ra’anana, Israel, Sept. 17, 2026 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN, FSE:C80) (“Rail Vision” or the “Company”), an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems, today announced the launch of YardFlow^™, its leading solution for industrial and freight railyards, designed to address a broad range of operational requirements across diverse yard environments.

The existing YardFlow Flex^™ (formerly ShuntingYard) remains available as a specialized multi-spectral option for special railyard applications and use cases in the industry, requiring enhanced performance in harsh weather and low-visibility conditions, providing customers with a choice tailored to their specific operational needs.

The Company believes that YardFlow will also support Rail Vision’s expanding commercial collaboration with Railserve, a Marmon Rail company. As previously announced, in 2024, Rail Vision and Railserve entered into a commercialization agreement for the deployment of the Company’s AI-based railyard systems and, in May 2026, signed a non-binding MOU to explore additional deployments, railcar mover applications, broader railyard solutions and other commercial opportunities. YardFlow is designed, among other applications, to address these types of applications as Rail Vision and Railserve continue to explore opportunities to expand their collaboration.

“YardFlow was developed based on years of extensive experience and valuable customer feedback, mainly based on our ongoing collaboration with Railserve. We believe that these insights are helping us to set a new standard for the market,” said David BenDavid, Chief Executive Officer of Rail Vision. “We have optimized our platform to provide a high-performance and cost-effective solution tailored to the evolving needs of dynamic yard environments, enabling us to bring our technology to a much broader customer base.”

Powered by high-sensitivity electro-optical vision sensors and proprietary deep-learning algorithms, YardFlow detects on-track or near-track hazards at distances of up to 200 meters (650 ft) and provides real-time alerts to help operators prevent incidents and maintain continuous switching operations. Its compact, modular structure enables simple installation across switching locomotives and railcar movers in freight and industrial rail operations, while built-in video recording and analytics provide actionable operational insights.

For more information about YardFlow, visit railvision.io/yardflow/

About Rail Vision Ltd.

Rail Vision (Nasdaq: RVSN, FSE: C80) is an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems. The Company develops and commercializes proprietary, electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, Rail Vision’s technology enhances safety, improves operational efficiency, and supports continuity across deployments.

The Company’s cloud-based platform complements its products by transforming railway operational data into actionable insights that help optimize performance, reduce downtime, and improve safety. As the Company expands its global footprint, it delivers AI-driven perception that supports safer operations, reduces operational risk, and enables the transition to fully autonomous operations.

Rail Vision holds a 51% stake in Quantum Transportation, which has an exclusive sub-license for rail technologies under an innovative pending patent in quantum error correction owned by Ramot, the technology transfer company of Tel Aviv University.

For more information, please visit https://www.railvision.io/

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected commercialization, deployment, capabilities, performance and benefits of YardFlow; the potential expansion of the Company’s collaboration with Railserve and related commercial opportunities; the ability of YardFlow to serve a broad range of railyard applications; and the Company’s future business plans, objectives and growth opportunities. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the SEC on March 31, 2026. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Rail Vision is not responsible for the contents of third-party websites.

Investor Relations:
Michal Efraty
investors@railvision.io

Founder of The LSM Group to support KALA’s growth across its existing business and potential acquisitions

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) — KALA BIO, Inc. (Nasdaq: KALA) (“KALA” or the “Company”) today announced that Yenvy Truong, founder of The LSM Group, has joined the Company’s advisory team. Ms. Truong will support management as KALA grows its existing business and evaluates opportunities to expand it, including through acquisitions.

Ms. Truong has spent roughly two decades in healthcare operations, including building and operating diagnostic laboratories. She has founded, scaled, and advised healthcare and life sciences companies across genomics, longevity, remote patient monitoring, digital musculoskeletal care, and metabolic medicine, through mergers, acquisitions, and growth financings totaling more than $200 million in transaction and enterprise value.

KALA is focused on expanding its business in diagnostics, genetic testing, and other areas of preventive and connected health, all enhanced by AI. That growth may come from the Company’s existing business, commercial agreements such as its exclusive distribution and reseller agreement with Virotek Inc., new services, and acquisitions. The Company believes Ms. Truong’s operating experience and industry relationships will provide it with insight into opportunities that align with those goals.

“Our focus is growth, starting with the business and agreements we already have,” said Avi Minkowitz, Chief Executive Officer of KALA. “Acquisitions can add to that, but only when they fit. Yenvy has built and run diagnostics and biotech/healthcare businesses and understands what it takes to scale them. She gives us a clearer view of where the right opportunities are, whether that is a new service, a new partner, or a company we bring into KALA.”

“KALA has a clear plan to grow its business and to expand where it makes sense. I’m looking forward to working with Avi and the team to identify opportunities that fit that plan and to help build long-term value,” said Ms. Truong.

Ms. Truong serves as an advisor to the Company and is neither an officer nor an employee of KALA.

About Kala Bio, Inc. (NASDAQ: KALA)

KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.

Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. Kala is advancing an agentic transformation strategy for biomedical organizations through Researgency.ai, a platform designed to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows. The Company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector.

Kala believes the future of biomedical innovation is in agentic systems.

For more information, visit www.kalarx.com and Researgency.ai

About The LSM Group

The LSM Group is a healthcare advisory firm working at the intersection of healthcare, life sciences, AI, and capital strategy. Founded by Yenvy Truong, the firm advises investors and operators on diagnostics, specialty pharmaceutical assets, applied AI in regulated environments, and longevity, and maintains a domain expert panel that evaluates companies before capital is committed.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategic initiative to build an AI infrastructure platform for the biotechnology industry; plans to develop and deploy the Researgency AI platform both internally and to external clients; expectations regarding the potential benefits of AI-driven analytical tools; plans to reassess historical datasets and identify new therapeutic indications; expectations regarding the AI drug discovery market and industry trends; expectations regarding the Company’s ability to generate recurring platform revenue; plans regarding potential partnerships, client deployments, or technology licensing opportunities; expectations regarding the Company’s competitive position and the differentiation of its on-premises deployment model; the potential exercise of development continuation or renewal options under the Agreement; and other statements that are not historical facts. It also includes statements regarding the proposed distribution partnership with Virotek, including the negotiation and execution of definitive agreements and the anticipated benefits and timing thereof. 

The Company used words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions to identify these forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements to be materially different from those expressed or implied by such statements. Important factors that could cause such differences include, but are not limited to: risks that AI technologies may not produce expected results in drug discovery or development; risks related to the development, deployment, and performance of the Researgency platform; risks that the Company may not successfully attract or retain external platform clients; risks that the platform-as-a-service business model may not generate anticipated revenues; risks that the Company’s product candidates may not be successfully developed or commercialized; risks related to the Company’s limited cash resources and ability to continue as a going concern; risks that the third-party information contained herein was not accurate at the time it was published and/or does not accurately predict the future; risks related to the Company’s ability to raise future capital and the possibility that market conditions may limit the Company’s ability to raise capital on favorable terms; risks related to the Company’s ability to regain compliance with Nasdaq listing requirements; competition from larger, better-resourced companies including major technology and pharmaceutical companies; dependence on key personnel and third-party technology providers; the accuracy of third-party market forecasts and projections cited herein; risks that the Company may elect not to expand or continue its deployment of the Researgency platform beyond the initial term; risks that Younet may not perform its obligations under the Agreement; and other risks detailed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K as they may be revised in the Company’s Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and other filings with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this release, and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Contact:

Avi Minkowitz
Chief Executive Officer, KALA BIO, Inc.
am@kalarx.com
www.kalarx.com | www.Researgency.ai

~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occurred in 24.0% of Patients Versus the Prespecified Historical Benchmark of 56.4% (P=0.001) ~

~ 84% of Patients Had Grade 0 Hearing Loss by Brock Criteria; No Grade 3 or Grade 4 Hearing Loss Was Observed ~

~ Objective Responses Observed in 23 of 24 Evaluable Patients (95.8%); Prospective Pharmacokinetic Analyses Provide New Mechanistic Insight Supporting the Six-Hour PEDMARK^® Administration Interval for Pediatric & Adolescent and Young Adult (AYA) Patients ~

~ Building Upon the Pivotal Children’s Oncology Group (COG) Protocol ACCL0431 & SIOPEL 6 Studies, STS-J01 Represents Third Study to Demonstrate that PEDMARK^® Showed No Interference with Cisplatin Antitumor Activity ~

RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2026 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the oral presentation of detailed results from the investigator-initiated Phase 2 STS-J01 clinical trial evaluating PEDMARK^® (sodium thiosulfate injection) for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan. The data will be presented today during the 58^th Annual International Society of Pediatric Oncology (SIOP) Annual Meeting in San Antonio, TX.

PEDMARK^® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors, and is also recognized by the National Comprehensive Cancer Network with a 2A endorsement for use in AYA patients.

The study enrolled 33 patients across 11 institutions in Japan, including 27 patients in the primary cohort and six in exploratory cohorts. Key study findings include:

• Among the 25 patients comprising the primary efficacy population, ASHA-defined hearing loss occurred in 24.0% (6/25), significantly lower than the prespecified historical benchmark of 56.4% (P=0.001).
• Nineteen of 25 patients (76.0%) remained free of ASHA-defined hearing loss. By Brock criteria, 84.0% of patients had Grade 0 hearing loss, and no patient experienced Grade 3 or Grade 4 hearing loss.
• Objective tumor responses were observed in 23 of 24 evaluable patients (95.8%), providing reassuring clinical context for delayed PEDMARK^® administration six hours following cisplatin.
• Prospective pharmacokinetic analyses further characterized the interaction between PEDMARK^® and cisplatin-derived platinum and provide mechanistic support for the six-hour administration strategy for pediatric and adolescent and young adult (AYA) patients.

“The clinical and pharmacologic findings of STS-J01 are compelling. We observed a significant reduction in hearing loss, with no Grade 3 or Grade 4 hearing loss by Brock criteria, alongside a 95.8% objective response rate in evaluable patients. The prospective pharmacokinetic analyses further provide important mechanistic insight into why the six-hour interval matters, supporting a model in which PEDMARK^® acts on residual circulating and exchangeable platinum after cisplatin has had time to distribute and initiate its antitumor activity. Together, these findings add an important independent body of evidence supporting the clinical rationale for delayed PEDMARK^® administration,” said Pierre S. Sayad, PhD, M.S., chief medical officer of Fennec Pharmaceuticals.

The safety profile was consistent with the known tolerability profile of PEDMARK^® and the expected toxicities of cisplatin-containing chemotherapy. No serious adverse event was attributed to PEDMARK^®, and no Grade 4 PEDMARK^®-related toxicity was observed.

“For patients navigating cancer in Japan, the ability to successfully treat their tumors while preserving hearing can have a profound impact on their lives long after treatment ends. Cisplatin remains an important and effective treatment, but the risk of permanent hearing loss represents a significant unmet need, particularly for children and young people who may live with its consequences for the rest of their lives,” said Eiso Hiyama, M.D., PhD, lead investigator and professor in the Department of Pediatric Surgery at Hiroshima University Hospital in Hiroshima, Japan. “The results from STS-J01 are encouraging because they demonstrate significant hearing protection and provide reassuring clinical context regarding antitumor activity with delayed PEDMARK^® administration. We believe that these results provide further support and confidence in PEDMARK^® for healthcare professionals.”

Fennec is pursuing registration in Japan and is currently exploring partnering or licensing opportunities for PEDMARK^®.

About the STS-J01 Study
STS-J01 is a Phase 2, investigator-initiated, open-label, single-arm clinical trial designed to evaluate PEDMARK^® for the prevention of cisplatin-induced ototoxicity. The study enrolled 33 patients in two cohorts: 27 children ages 3-18 years (primary cohort), and 6 patients in exploratory cohorts, all with localized-stage solid tumors, including neuroblastoma, hepatoblastoma, germ cell tumors, bone and soft tissue sarcomas, medulloblastoma, and atypical teratoid rhabdoid tumors. Patients received PEDMARK^® intravenously six hours after cisplatin infusion, with dosing adjusted by body weight. The primary endpoint was the incidence of hearing impairment at the end of treatment in the 3- to 18-year-old cohort, assessed according to  American Speech-Language-Hearing Association (ASHA) criteria. Secondary endpoints included safety, antitumor efficacy, pharmacokinetics, and incidence of hearing loss as measured by Brock grading. Exploratory measures included longitudinal audiometric follow-up and validation of surrogate hearing tests.

About Cisplatin-Induced Ototoxicity
Cisplatin and other platinum-based chemotherapies are widely used to treat solid tumors and have been vital in improving survival rates. Unfortunately, these life-saving treatments often result in permanent, irreversible hearing loss, also known as ototoxicity.¹

Hearing loss from cisplatin treatment is not rare. Studies show that between 60-90% of patients treated with cisplatin may develop hearing loss, depending upon the dose and duration of chemotherapy.² Many of those treated with cisplatin will require lifelong hearing aids or cochlear implants, which can be helpful for some, but do not reverse the hearing loss and can be costly over time.³ Treatment-induced hearing loss can reduce quality of survivorship as it impacts many aspects of life, such as speech and language skills, academic performance, social-emotional development, career potential and the ability to live independently.^4,5 While audiologic monitoring is recommended to help manage ototoxicity, it is currently underutilized in certain cancer patient populations.

PEDMARK^® (sodium thiosulfate injection)
PEDMARK^® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients 1 month of age and older with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the first and only therapeutic agent with proven efficacy and safety data with an established dosing regimen, across two open-label, randomized Phase 3 clinical studies, the Children’s Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Additionally, PEDMARK^® is recommended for the adolescent and young adult (AYA) population by the National Comprehensive Cancer Network, or NCCN, with a 2A endorsement.

Approximately 500,000 patients in the U.S. are diagnosed annually with cancers that could be treated with a platinum-based chemotherapy.^6,7 The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of those treated will require lifelong hearing aids. Until the FDA approval of PEDMARK, there were no preventative agents for this hearing loss. Patients with hearing loss resulting from cancer treatment have a statistically significant worse quality of life compared with peers who have no hearing loss.^8,9

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Indications and Usage
PEDMARK^® (sodium thiosulfate injection) is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors.

Limitations of Use
The safety and efficacy of PEDMARK have not been established when administered following cisplatin infusions longer than 6 hours. PEDMARK may not reduce the risk of ototoxicity when administered following longer cisplatin infusions, because irreversible ototoxicity may have already occurred.

Important Safety Information
PEDMARK is contraindicated in patients with history of a severe hypersensitivity to sodium thiosulfate or any of its components.

Hypersensitivity reactions occurred in 8% to 13% of patients in clinical trials. Monitor patients for hypersensitivity reactions. Immediately discontinue PEDMARK and institute appropriate care if a hypersensitivity reaction occurs. Administer antihistamines or glucocorticoids (if appropriate) before each subsequent administration of PEDMARK. PEDMARK may contain sodium sulfite; patients with sulfite sensitivity may have hypersensitivity reactions, including anaphylactic symptoms and life-threatening or severe asthma episodes. Sulfite sensitivity is seen more frequently in people with asthma.

PEDMARK is not indicated for use in pediatric patients less than 1 month of age due to the increased risk of hypernatremia or in pediatric patients with metastatic cancers.

Hypernatremia occurred in 12% to 26% of patients in clinical trials, including a single Grade 3 case. Hypokalemia occurred in 15% to 27% of patients in clinical trials, with Grade 3 or 4 occurring in 9% to 27% of patients. Monitor serum sodium and potassium levels at baseline and as clinically indicated. Withhold PEDMARK in patients with baseline serum sodium greater than 145 mmol/L.
Monitor for signs and symptoms of hypernatremia and hypokalemia more closely if the glomerular filtration rate (GFR) falls below 60 mL/min/1.73m².

Administer antiemetics prior to each PEDMARK administration. Provide additional antiemetics and supportive care as appropriate.

The most common adverse reactions (≥25% with difference between arms of >5% compared to cisplatin alone) in SIOPEL 6 were vomiting, nausea, decreased hemoglobin, and hypernatremia. The most common adverse reaction (≥25% with difference between arms of >5% compared to cisplatin alone) in COG ACCL0431 was hypokalemia.

Please see full Prescribing Information for PEDMARK^® at: www.PEDMARK.com.

About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK^® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI^Ò.

In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI^® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in multiple countries.  

PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.

For more information, please visit www.fennecpharma.com and follow on LinkedIn.

Forward Looking Statements
Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline and other goals, plans and prospects, including our commercialization plans respecting PEDMARK^®/PEDMARQSI^®, the market opportunity for and market impact of PEDMARK^®/ PEDMARQSI^®, its potential impact on patients and anticipated benefits associated with its use, future commercial and regulatory milestone and royalty payments from Norgine, potential regional partnering or licensing opportunities for PEDMARK^®/PEDMARQSI^®, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2025. Fennec disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

PEDMARK^® PEDMARQSI^® and Fennec^® are registered trademarks of Fennec Pharmaceuticals Inc.

©2026 Fennec Pharmaceuticals Inc. All rights reserved.

For further information, please contact:

Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299

Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com

---

¹ Sheth S et al. Mechanisms of Cisplatin Ototoxicity and Progress in Otoprotection. Frontiers in Cellular Neuroscience. 2017, Vol. 11.
² Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458-469
³ Landier W. Ototoxicity and Cancer Therapy. Cancer. June 2016 Vol. 122, No.11: 1647-1658.
⁴ Clemens E, van den Heuvel-Eibrink MM, Mulder RL, et al. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol. 2019;20(1):e29-e41
⁵ Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63(7):1152-1162.
⁶ Chattaraj A et al. Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies. JCO Oncol Pract. 2023;19
⁷ Freyer DR et al. Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017;18(1):63-74.
⁸ Rajput K, Edwards L, Brock P, Abiodun A, Simpkin P, Al-Malky G. Ototoxicity-induced hearing loss and quality of life in survivors of paediatric cancer. Int J Pediatr Otorhinolaryngol. 2020;138:110401. doi:10.1016/j.ijporl.2020.110401
⁹ Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: a report from the children’s oncology group. Pediatr Blood Cancer. 2016;63(7):1152-1162.

MONTREAL, Sept. 17, 2026 (GLOBE NEWSWIRE) — NanoXplore Inc. (“NanoXplore” or the “Company”) (TSX: GRA and OTCQX: NNXPF) today announced that it has been selected as a qualified supplier under the Government of Canada’s Defence Drone Initiative (“DDI”) Marketplace. NanoXplore applied under, and was approved in Stream 5 (Innovation and Experimentation).

The qualification covers both NanoXplore’s graphene-enhanced composite components and the graphene enhanced lithium-ion battery cells produced by VoltaXplore Inc. Qualification under the DDI establishes NanoXplore and VoltaXplore as part of the Government of Canada’s pre-qualified supplier pool and enables the Company to participate in future opportunities related to uncrewed and autonomous systems in support of the Canadian Armed Forces and Canadian Coast Guard.

“Qualification under the Defence Drone Initiative Marketplace recognizes the vital role that advanced Canadian materials and battery cells can play in uncrewed and autonomous systems,” said Rocco Marinaccio, President and Chief Executive Officer of NanoXplore. “Through NanoXplore’s graphene-enhanced composites and VoltaXplore’s graphene-enhanced lithium-ion 21700 cells, we are positioned to domestically produce lightweight structural components and high-performance battery cells as part of Canada’s sovereign defence supply chain.”

Launched by the Government of Canada in July 2026 and led by the Department of National Defence and the Defence Investment Agency, the Defence Drone Initiative is designed to accelerate the development, testing, adaptation and production of Canadian uncrewed and autonomous systems while strengthening domestic defence industrial capacity and sovereign capability. The DDI Marketplace connects the Department of National Defence and the Canadian Armed Forces with pre-qualified Canadian suppliers through a streamlined procurement mechanism.

The DDI Marketplace is being established as the Government of Canada advances a planned investment of approximately $180 billion in direct defence procurement over the next decade and has identified uncrewed and autonomous systems as one of ten sovereign capability priorities under Canada’s Defence Industrial Strategy.

About NanoXplore Inc.

NanoXplore is a graphene company and the largest manufacturer and supplier of high-volume graphene powder for use in multiple end markets with up to 5,000 tonnes of annual production capacity. The Corporation also provides standard and custom graphene-enhanced plastic and composite products to customers in the recreational vehicle, transportation, packaging, electronics, and other industrial sectors, and manufactures silicon-graphene-enhanced Li-ion batteries for the energy storage, industrial, and defense markets. NanoXplore holds over 100 patents and patent applications protecting its intellectual property, products, and process knowledge, and is one of a limited number of companies authorized to produce and sell graphene at commercial scale in Canada, the United States, the United Kingdom, and the European Union, holding Environment and Climate Change Canada (ECCC) and Health Canada certification, U.S. EPA certification, and UK and EU REACH registrations.

Please visit www.nanoxplore.ca  

For further information, please contact:  

Pedro Azevedo
Chief Financial Officer 
pedro.azevedo@nanoxplore.ca
Tel: +1 438 476 1973 

       

Approximately $93 million investment advances fleet modernization efforts while continuing a relationship that has supported public transportation across the Houston region since 1991

ST. CLOUD, Minn., Sept. 17, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, subsidiary New Flyer of America Inc. (New Flyer), today announced an order from the Houston Metropolitan Transit Authority (METRO) for 100 Xcelsior^® 40-foot compressed natural gas buses. The order was added to New Flyer’s firm backlog in the second quarter of 2026.

The purchase, valued at approximately $93 million, is supported by funding from the Federal Transit Administration’s (FTA) 2025-2026 Low- or No-Emission (Low-No) Program and Bus and Bus Facilities Projects. The new buses will replace end-of-life vehicles, helping METRO support efficient, lower-emission transit service across the Houston region. The initiative is being undertaken in conjunction with upgrades to select METRO facilities that will increase compressed natural gas (CNG) fueling capacity.

“For more than 30 years, METRO and NFI have worked together to support safe, dependable transit for the Houston region,” said Chris Stoddart, President, North American Bus and Coach, NFI. “We’re honored to continue that partnership with New Flyer Xcelsior CNG buses that will help enhance service for riders, support METRO’s ongoing fleet renewal efforts, and continue advancing cleaner public transportation solutions for the communities it serves.”

METRO is the primary public transportation provider in the Houston region, delivering safe, reliable, and integrated mobility solutions across the City of Houston, most of Harris County, and surrounding communities. Since beginning operations in 1979, METRO has evolved into a comprehensive, multimodal system spanning approximately 1,300 miles, connecting millions of residents to employment centers, education, healthcare, and essential services through an extensive network of bus, light rail, and accessible transit options.

Today, METRO serves a population of approximately four million people and provides more than 76 million passenger trips annually, playing a pivotal role in supporting mobility and economic growth in one of North America’s largest metropolitan regions. Bus service forms the backbone of the system, accounting for the majority of the ridership and enabling frequent, high-capacity connections across the region’s diverse communities.

“CNG allows METRO to deliver the reliable service our customers depend on while operating a cleaner, more efficient fleet,” said Kurt Luhrsen, Interim COO at METRO. “As we replace aging buses, we have an opportunity to reduce emissions and make responsible choices that benefit both our riders and the Houston region. CNG is an important part of that commitment.”

This latest order further strengthens the longstanding relationship between NFI and METRO, which has included New Flyer transit buses and MCI motorcoaches since 1991. Together, the organizations continue working to support essential transportation services, system investment, and improved transit access across the Houston metropolitan region.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer^® (heavy-duty transit buses), MCI^® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC^® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

About New Flyer

New Flyer is North America’s heavy-duty transit bus leader and offers the most advanced product line under the Xcelsior^® and Xcelsior CHARGE^® brands. It also offers infrastructure development through NFI Infrastructure Solutions™, a service dedicated to providing safe, sustainable, and reliable charging and mobility solutions. New Flyer actively supports over 35,000 heavy-duty transit buses (New Flyer, NABI, and Orion) currently in service, of which 8,600 are powered by electric motors and battery propulsion and 1,900 are zero-emission. Further information is available at www.newflyer.com.

Forward-Looking Statements

This press release may contain forward-looking statements relating to expected future events and financial and operating results of NFI that involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures) and economic conditions of and funding availability for customers to purchase buses and to purchase parts or services (including as a result of recent U.S. policy developments); customers may not exercise options to purchase additional buses; the ability of customers to suspend or terminate contracts for convenience; production may be delayed or production rates may be decreased as a result of ongoing and future supply chain disruptions and shortages of parts and components, shipping and freight delays, and disruption to and shortage of labor supply; and the other risks and uncertainties discussed in the materials filed with the Canadian securities regulatory authorities and available on SEDAR at www.sedarplus.ca.  

Due to the potential impact of these factors, NFI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. 

For media inquiries, please contact: 
Melissa Schnee 
P: 385.910.6861 
Melissa_Schnee@newflyer.com 

For investor inquiries, please contact: 
Stephen King 
P: 204.792.1300 
Stephen.King@nfigroup.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/296fd9f9-75eb-48f1-8124-e3f769ae17e9

This press release was published by a CLEAR® Verified individual.

ATLANTA, Sept. 17, 2026 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that it has completed the sale of its CAR Auto Finance operations (“CAR”) to an unaffiliated third party.

CAR comprised 100% of the Company’s Auto Finance segment. Following the transaction, Atlanticus will no longer operate an Auto Finance segment. Total consideration to Atlanticus was approximately $71.2 million, consisting of $56.2 million in cash and a $15.0 million seller note. Approximately 154 team members associated with CAR are transitioning to the buyer in connection with the transaction.

“We are pleased to announce the completion of the sale of CAR,” said Jeff Howard, President and Chief Executive Officer of Atlanticus. “CAR has been a valuable part of Atlanticus for many years, and I want to thank the entire CAR team for their many contributions to our success. The transaction strengthens our balance sheet and allows us to concentrate our capital and management resources on the consumer credit products where we see the greatest opportunities for long-term value creation and growth.”

Atlanticus expects to use the cash proceeds from the sale to reduce debt and invest in higher-growth product lines.

About Atlanticus Holdings Corporation

Empowering Better Financial Outcomes for Everyday Americans

Atlanticus Holdings Corporation empowers better financial outcomes for Everyday Americans by enabling bank, retail, and healthcare partners to offer more inclusive financial solutions to consumers. Leveraging proprietary technology and advanced analytics, Atlanticus applies more than 30 years of operating experience, servicing over 23 million customers and more than $53 billion in consumer loans, to support lenders across a broad range of consumer credit products. These offerings span retail and healthcare private-label credit and general purpose credit cards, through an omnichannel platform, including strategic partnerships.

Atlanticus is guided by the principles of responsible lending, smart innovation, and expanding access to credit for consumers working toward a stronger financial future.

Forward-Looking Statements

This press release contains forward-looking statements that reflect the Company’s current views regarding, among other things, the expected transition of employees, the Company’s intended use of proceeds from the transaction, capital allocation and future investment and growth opportunities. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those included in the forward-looking statements. These risks and uncertainties include those risks described in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements speak only as of the date on which they are made, and, except to the extent required by federal securities laws, the Company disclaims any obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. In light of these risks and uncertainties, there is no assurance that the events or results suggested by the forward-looking statements will in fact occur, and you should not place undue reliance on these forward-looking statements.

Contact:
Investor Relations, investors@atlanticus.com
Dan Mauch, daniel.mauch@atlanticus.com
Sara Savarino, sara.savarino@atlanticus.com